Use of beta-blockers in COPD: mythical risk or justified benefit?


DOI: https://dx.doi.org/10.18565/therapy.2019.5.27-35

Adasheva T.V., Bolieva L.Z., Lee V.V., Malyavin A.G.

1) A.I. Evdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia 2) North Ossetia–Alania State medical Academy of the Ministry of Healthcare of Russia, Vladikavkaz
The article analyzes the results of recent studies, meta-analyses, justifying the effectiveness and safety of the use of beta-blockers in COPD patients. The positive respiratory effects of β-blockers, such as a decrease in the intensity of systemic inflammation, a decrease in the number of exacerbations and hospitalizations due to the exacerbation of COPD, are discussed. The latest experimental and clinical data on the synergistic interaction of beta-blockers and beta-agonists are presented.
Keywords: chronic obstructive pulmonary disease, beta-blockers, cardiovascular disease
Read entire article

Literature


  1. Lozano R., Naghavi M., Foreman K. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2095–128.

  2. Global Strategy for the Diagnosis, Management and Prevention of COPD (GOLD 2019). 2019; 155.

  3. Обрезан А.Г., Куколь Л.В., Эрднеев Б.А. Хроническая обструктивная болезнь легких и коморбидные кардиоваскулярные заболевания у лиц пожилого и старческого возраста: проблемы диагностики лечения (обзор литературы). Вестник СПбГУ. 2010; 11(2): 51–66.

  4. Авдеев С.Н., Баймаканова Г.Е. Сердечно-сосудистые заболевания у больных ХОБЛ: проблемы выбора лекарственных препаратов. Атмосфера. Пульмонология и аллергология. 2008; 2: 3–8

  5. Lahousse L., Niemeijer M.N., van den Berg M.E. et al. Chronic obstructive pulmonary disease and sudden cardiac death: the Rotterdam study. Eur Heart J. 2015; 36(27):1754–61.

  6. Sin D.D., Paul Man S.F. A curious case of b-blockers in chronic obstructive pulmonary disease. Arch Intern Med. 2010; 170: 849–50.

  7. Corrao S., Santalucia P., Argano C. et al. Gender differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study. Eur J Intern Med. 2014; 25: 617–23.

  8. de Miguel Díez J., Chancafe Morgan J., Jiménez García R. The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis. 2013; 8: 305–12.

  9. Rothnie K.J., Yan R., Smeeth L. et al. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open 2015; 5:e007824.

  10. Stefan M.S., Bannuru R.R., Lessard D. et al. The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction: a ten-year retrospective observational study. Chest 2012; 141:1441–48.

  11. Miravitlles M., Calle M., Soler-Cataluña J.J. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol. 2012; 48: 86–98.

  12. Meyer A., Butler K., Long C. et al. Beta-blockers and COPD – inappropriate avoidance? Proceedings of Mid-South Regional Pharmacy Residents Conference. 2013; 66.

  13. Stefan M.S., Rothenberg M.B., Priva A. et al. Association between beta-blocker therapy and outcomes in patients hospitalized with acute exacerbations of chronic obstructive lung disease with underlying ischemic heart disease, heart failure or hypertension. Thorax. 2012; 67: 977–84.

  14. Государственный реестр лекарственных средств https://grls.rosminzdrav.ru/

  15. Bartels M.N., Gonzalez J.M., Kim W. et al. Oxygen supplementation and cardiac-autonomic modulation in COPD. Chest. 2000; 118(3): 691–96.

  16. Curtis B.M., O’Keefe J.H. Jr. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc. 2002; 77(1): 45–54.

  17. Heindl S., Lehnert M., Criée C.P. et al. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med. 2001; 164(4): 597–601.

  18. Cook S., Togni M., Schaub M.C. et al. High heart rate: a cardiovascular risk factor? Eur Heart J. 2006; 27(20): 2387–93.

  19. Baker J.G., Wilcox R.G. β-Blockers, heart disease and COPD: current controversies and uncertainties Thorax. 2017; 72: 271–76.

  20. Angeloni E., Melina G., Roscitano A. et al. β-blockers improve survival of patients with chronic obstructive pulmonary disease after coronary artery bypass grafting. Ann Thorac Surg. 2013; 95: 525–31.

  21. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998; 339: 489–97.

  22. Mentz R.J., Wojdyla D., Fiuzat M. et al. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol. 2013; 111: 582–87.

  23. Mentz R.J., Schulte P.J., Fleg J.L. et al. Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from heart failure and a controlled trial investigating outcomes of exercise training (HFACTION). Am Heart J. 2013; 165: 193–99.

  24. Rutten F.H., Zuithoff P.A., Hak E. et al. β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010; 170: 880–87.

  25. van Gestel Y.R., Hoeks S.E., Sin D.D. et al. Impact of cardioselective bblockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med. 2008; 178: 695–700.

  26. Short P.M., Lipworth S.I., Elder D.H. et al. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011; 342: d2549.

  27. Etminan M., Jafari S., Carleton B. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012; 12: 48.

  28. Farland M.Z., Peters C.J., Williams J.D. et al. Beta-blocker use and incidence of chronic obstructive pulmonary disease exacerbations. Ann Pharmacother. 2013; 47: 651–56.

  29. Callaerts-Vegh Z., Evans K.L., Dudekula N. et al. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA. 2004; 101: 4948–53.

  30. Nguyen L.P., Omoluabi O., Parra S. et al. Chronic exposure to betablockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol. 2008; 38: 256–62.

  31. Egred M., Shaw S., Mohammad B. et al. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. Q J Med. 2005; 98: 493–97.

  32. Rasmussen D.B., Bodtger U., Lamberts M. Beta-blocker, aspirin and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. Eur Heart J Qual Care Clin Outcomes. 2019. doi: 10.1093/ehjqcco/qcy063

  33. Cargill R.I., Kiely D.G., Lipworth B.J. Adverse effects of hypoxaemia on diastolic filling in humans. Clin Sci (Lond). 1995; 89: 165–69.

  34. Kiely D.G., Cargill R.I., Grove A. et al. Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol. Thorax. 1995; 50: 1062–66.

  35. Patel A.R., Donaldson G.C., Mackay A.J. et al. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest. 2012; 141: 851–57.

  36. Patel A.R., Kowlessar B.S., Donaldson G.C. et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 188: 1091–99.

  37. Williams M.C., Murchison J.T., Edwards L.D. et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax. 2014; 69: 718–23.

  38. Chen J., Radford M.J., Wang Y. et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol. 2001; 37(7): 1950–56.

  39. Andell P., Erlinge D., Smith J.G. et al. β-blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study. J Am Heart Assoc. 2015; 4: e001611.

  40. Su T-H., Chang S-H., Kuo C-F. et al. β-blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: A nationwide population-based observational study. PLoS One. 2019; 14(3): e0213187.

  41. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2016; 37: 2129–200.

  42. Sessa M., Mascolo A., Scavone C. et al. Long-Term Clinical Impact of Beta-Blockers Selectivity to carvedilol. Frontiers in Pharmacology. 2018; 9: 1212.

  43. Hawkins N.M., Wang D., Petrie M.C. et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail. 2010; 12(6): 557–65.

  44. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016; 37:2893–2962.

  45. Shibata Y., Watanabe T., Osaka D. et al. Impairment of pulmonary function is an independent risk factor for atrial fibrillation: The Takahata Study. Int J Med Sci. 2011; 8(7): 514–22.

  46. Camsari A., Arikan S., Avan C. et al. Metoprolol, a β1-selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart Vessels. 2003; 18: 188–92.

  47. Jabbour A., Macdonald P.S., Keogh A.M. et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010; 55: 1780–87.

  48. Dungen H.D., Apostolovi С.S., Inkrot S. et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail. 2011; 13: 670–80.

  49. Hawkins N.M., MacDonald M.R., Petrie M.C. et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail. 2009; 11: 684–90.

  50. Bhatt S.P., Wells J.M., Kinney G.L. et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax. 2016; 71(1): 8–14.

  51. Fuente-Maestu L., Calle M., Ortega-González A. Multicentric study on the beta-blocker use and relation with exacerbations in COPD. Respir Med. 2014; 108(5): 737–44.

  52. Wedzicha J.A., Banerji D., Chapman K.R. et al. Indacaterol-glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med. 2016; 374: 2222–34.

  53. Calzetta L., Rogliani P., Matera M.G. et al. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016; 149: 1181–96.

  54. Matera M.G., Rogliani P., Calzetta L. et al. Safety considerations with dual bronchodilator therapy in COPD: an update. Drug Saf. 2016; 39: 501–08.

  55. Oba Y., Sarva S.T., Dias S. Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016; 71: 15–25.

  56. Petta V., Perlikos F., Loukides S. et al. Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease. Heart Fail Rev. 2017; 22(6): 753–63.

  57. Dransfield M.T., McAllister D.A., Anderson J.A. et al. β-Blocker therapy and clinical outcomes in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk. An Observational Substudy of SUMMIT. Ann Am Thorac Soc. 2018; 15(5): 608–14.

  58. Rinaldi B., Capuano A., Gritti G. et al. Effects of chronic administration of b-blockers on airway responsiveness in a murine model of heart failure. Pulm Pharmacol Ther. 2014; 28(2): 109–13.

  59. Rinaldi B., Donniacuo M., Sodano L. et al. Effects of chronic treatment with the new ultra-long-acting β2-adrenoceptor agonist indacaterol alone or in combination with the β1-adrenoceptor blocker metoprolol on cardiac remodelling. Br J Pharmacol. 2015; 172(14): 3627–37.

  60. Khan M., Mohsin S., Avitabile D. et al. β-Adrenergic regulation of cardiac progenitor cell death versus survival and proliferation. Circ Res. 2013; 112(3): 476–86.

  61. Rutten F.H., Hoes A.W. Chronic obstructive pulmonary disease: a slowly progressive cardiovascular disease masked by its pulmonary effects? Eur J Heart Fail. 2012; 14(4): 348–50.

  62. Lin R., Peng H., Nguyen L.P. et al. Changes in β2-adrenoceptor and other signaling proteins produced by chronic administration of β-blockers’ in a murine asthma model. Pulm Pharmacol Ther. 2008; 21(1): 115–24.

  63. Salpeter S., Ormiston T., Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005; 19(4): CD003566.

  64. Dezsi C.A., Szentes V. The real role of β-blockers in daily cardiovascular therapy. Am J Cardiovasc Drugs. 2007; 17: 361–73.

  65. Lindenfeld J., Albert N.M., Boehmer J.P.et al. Heart Failure Society of America: 2010 Comprehensive Heart Failure Practice Guidelines. J Card Fail. 2010; 16: e1–e194.

  66. Malerba M., Montuschi P., Radaeli A. et al. Role of beta-blockers in patients with COPD: current perspective. Drug Discov Today. 2015; 20: 129–35.

  67. McMurray J.J., Adamopoulos S., Anker S.D. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012; 22: 1787–47.

  68. Yancy C.W., Jessup M., Bozkurt B. et al. 2013 ACCF/AHA Guideline for the management of heart failure. J Am Coll Cardiol. 2013; 5: S0735–S1097.


About the Autors

Tatiana V. Adasheva, MD, professor of the Department of polyclinic therapy of A.I. Evdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia. Address: 107150, Moscow, 39/1. Losinoostrovskaya Str,. Tel.: +7 (499) 169-74-08. E-mail: adashtv@mail.ru
Laura Z. Bolieva, MD, professor, head of the Department of pharmacology with clinical pharmacology of North Ossetia–Alania State medical Academy of the Ministry of Healthcare of Russia. Address: 362019, Vladikavkaz, 40 Pushkinskaya Str.. Tel..: +7 (867) 256-63-50. E-mail: bolievalz@mail.ru
Vera V. Lee, MD, professor, associated professor of the Department of polyclinic therapy of A.I. Evdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia. Address: 107150, Moscow, 39/1. Losinoostrovskaya Str,. Tel.: +7 (499) 169-74-08.
Andrey G. Malyavin, MD, professor of the Department of phthisiology and pulmonology of A.I. Yevdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (916) 547-83-73. E-mail: maliavin@mail.ru


Similar Articles

Back to Content

Бионика Медиа